Global Crohn’s Disease Market and Seasonal Influenza Market 2018-2026: Key-Trends, Innovative Products, Key Market Events, Industry-Growth, and Emerging Players
Exhaustive Study for “Global Crohn’s Disease Market” and “Global Seasonal Influenza Market” is added on Orbisresearch.com database. The report covers the market landscape and growth prospects over the coming years. It also includes a discussion of the key vendors operating in this market.
Dallas, United States – December 11, 2018 /MarketersMedia/ —
Global Crohn’s Disease Market 2018-2026:
Crohn’s disease is a form of inflammatory bowel disease, which is comprised of two chronic autoimmune diseases that cause intestinal inflammation: Crohn’s disease and ulcerative colitis. In Crohn’s disease, chronic inflammation may affect any part of the gastrointestinal tract from the mouth to the anal area; however, Crohn’s disease occurs most commonly in the lower part of the small intestine (ileum) and in the large intestine. The pathophysiology of Crohn’s disease is complex, as the disease is characterized by recurring flares that evolve along with periods of inactivity and remission.
GlobalData estimates the 2016 sales for the Crohn’s disease market at approximately $9.0 billion across the 7MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK), and Japan. Based on insights gathered from key opinion leaders, it is anticipated that the pipeline drugs for Crohn’d disease will impact the treatment landscape. By the end of the forecast period in 2026, sales will increase to $13.8 billion at a compound annual growth rate of 4.4%. This growth will be driven by continued strong uptake of Johnson & Johnson’s interleukin 12/23 (IL-12/23) inhibitor Stelara in addition to the anticipated launches of IL-23 inhibitors, anti-integrin therapies, and novel oral therapies, which will provide more treatment options for physicians to choose from. Major barriers to the growth of the Crohn’s disease market during the forecasted years include patent expiries of key biologics will cause decreases in sales due to the launch of biosimilars and subsequent brand erosion, such as J&J’s Remicade and AbbVie’s Humira; pricing pressures and reimbursement issues; and the challenging environment for new market entrants given the established biologics market in Crohn’s disease.
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2398603
Scope:
The Key Events covered in this Crohn’s disease Dynamic Market Forecast include –
– Increased Competition for Phase III Oral Small Molecules
– Anti-interleukin Therapies to Drive Growth in the Crohn’s Disease Market
– Stem Cell Therapies to Fulfill an Unmet Need in a Niche Patient Population
Components of the slide deck include –
– Timeline of market-impacting events
– Key clinical trial landscape updates
– Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
– Overview of updates to the forecast model based on anticipated future impact of events
– Forward-looking events calendar listing expected key updates to the Crohn’s disease competitive space through March 2019
Other events included in the analysis include –
– Regulatory filings
– Approval decisions
– Pricing changes
– Patent litigation
– Clinical trial data announcements
– Clinical trial failures
– Clinical trial timeline updates.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2398603
Key Players:
• AbbVie
• Celgene
• Galapagos
• Genentech
• Gilead
• Johnson & Johnson
• Mesoblast
• RedHill Biopharma
• Shire
• Takeda
• TiGenix
• UCB
Reasons to buy:
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global Crohn’s disease market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Crohn’s disease market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify key pricing and reimbursement strategies.
Part 2:
Global Seasonal Influenza Market 2018-2026:
Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses designated as influenza types A, B, and C. The influenza A H1N1 and H3N2, and influenza B strains are those responsible for seasonal influenza infections. The symptoms of influenza are similar to those of the common cold, though they are usually more severe, have a sudden onset, last for one to two weeks, and are normally self-limiting without medical treatment. The very young, elderly, and patients with chronic illness such as diabetes, asthma, or cardiovascular disease are most at risk of complications due to influenza.
This report provides an assessment of the pipeline, clinical, and commercial landscape of seasonal influenza. Overall, GlobalData expects new drug approvals to drive a shift in the treatment and prophylaxis of seasonal influenza over the next decade (2016-2026).
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2398605
Scope:
This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include –
– Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by product type
– Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
– Commercial Assessment: leading marketed products, current and future players
– Competitive Landscape Analysis: key market events (2016-2026).
Reasons to buy:
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global seasonal influenza market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global seasonal influenza market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2398605
Key Players:
• AbbVie
• Adimmune
• Antigen Express
• Beijing Minhai Biotechnology
• Biken
• BiondVax Pharmaceuticals
• Codagenix
• Daiichi Sankyo
• Denka Seiken
• iBio
• Instituto Butantan
• Japan Vaccine Co
• Johnson & Johnson
• Medicago
• Mercia Pharma
• Merck & Co
• Sanofi Pasteur
• Vaxxas Pty
• Vivaldi Biosciences
Get More Information about this Report@ http://www.orbisresearch.com/reports/index/seasonal-influenza-competitive-landscape-to-2026
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Info:
Name: Hector Costello
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A.
Phone: +1 (214) 884-6817
Website: http://www.orbisresearch.com
Source: MarketersMedia
Release ID: 457824
Copyright © 1999-2013 SproutNews.com
